Natera (NTRA) On Prospera Coverage Expansion And Revenue Strength Looks Fully Valued

Natera (NTRA) stock is in focus after two key developments: a final local coverage determination expanding Prospera transplant test access and stronger than expected revenue growth supported by higher testing volumes.

See our latest analysis for Natera.

Natera’s recent developments appear to be reflected in its share price, with a 30.2% 90 day share price return and a very large 3 year total shareholder return that suggests momentum has been building over a longer period.

If Natera’s move has caught your attention, this could be a good moment to look at other healthcare testing and diagnostics plays using the 39 healthcare AI stocks

After a 30.2% 90 day run and a very large 3 year shareholder return, the key issue now is whether recent LCD progress and revenue strength leave Natera with meaningful upside ahead, or if most of the easy gains are already in the price.

Most Popular Narrative: 4% Overvalued

The most followed narrative puts Natera’s fair value at $260.05, slightly below the last close of $271.39. This sets up a tight valuation debate.

Increasing adoption and acceptance of advanced molecular diagnostics is driving sustained volume and revenue growth across Natera's diversified portfolio, with significant headroom remaining for further penetration, particularly in oncology (Signatera) and organ health (Prospera). This will likely boost top-line revenue.

Read the complete narrative.

Curious what justifies paying above that fair value line for Natera? The narrative leans heavily on compounding revenue, rising margins and a premium profit multiple usually reserved for market leaders.

Result: Fair Value of $260.05 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, there is still the risk that Natera’s heavy spending and intense MRD competition could limit the margin gains and premium multiples implied in the current narrative.

Find out about the key risks to this Natera narrative.

Another View: SWS DCF Points to Undervaluation

The first narrative argues Natera looks around 4% overvalued versus a $260.05 fair value. Yet the SWS DCF model suggests something very different, with an estimated future cash flow value of $559.54 per share, implying the current $271.39 price sits well below that level. Which story do you think fits your own expectations for Natera’s cash generation and risk?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Natera for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With such a mixed picture around Natera, it makes sense to move quickly, review the underlying data, and decide where you stand on the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Natera?

If Natera has sharpened your focus on where capital goes next, do not stop here. Broaden your watchlist now with targeted stock ideas before others get there first.

• Target resilience by reviewing companies highlighted in the 84 resilient stocks with low risk scores to see which stocks score well on downside protection.
• Hunt for potential value by scanning the 47 high quality undervalued stocks and spot stocks that combine quality fundamentals with prices that differ from intrinsic estimates.
• Strengthen your core holdings by using the solid balance sheet and fundamentals stocks screener (47 results) to identify companies with financial profiles designed to handle tougher conditions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com